Alembic Pharma bags USFDA nod for hypertension drug Diltiazem Hydrochloride ER

Vadodara: Alembic Pharmaceuticals Limited has announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Cardizem CD Extended-Release Capsules, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, of Bausch Health US, LLC.

Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension. Diltiazem hydrochloride may be used alone or in combination with other antihypertensive medications. It is also indicated for the management of chronic stable angina and angina due to coronary artery spasm.

Hypertension, also known as high blood pressure, is a medical condition where the force of the blood against the walls of the arteries is consistently too high. It is a common condition that can lead to serious health problems, such as heart disease, stroke, kidney damage, and more, if left untreated.

Read also: Alembic Pharma gets USFDA nod for Alcaftadine Ophthalmic Solution

Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg have an estimated market size of US$105.3 million for twelve months ending June 2024 according to IQVIA. Alembic has a cumulative total of 218 ANDA approvals (191 final approvals and 27 tentative approvals) from USFDA.

Read also: Alembic Pharma gets USFDA nod to Diltiazem Hydrochloride ER Capsules to treat hypertension